Appeal 2007-2523
Application 10/370,749
Presta also discloses that the “polypeptide variant may . . . comprise an
antibody or an immunoadhesin” (id. at col. 4, ll. 36-37).
Presta defines an “amino acid modification” as “the substitution or
deletion of the specified residue, or the insertion of at least one amino acid
residue adjacent the specified residue” (id. at col. 12, ll. 26-30). In addition,
Presta defines an “amino acid substitution” as “the replacement of at least
one existing amino acid residue . . . with another different ‘replacement’
amino acid residue” (id. at col. 12, ll. 34-37). Presta states that the
replacement residue may be a naturally occurring amino acid residue “(i.e.
encoded by the genetic code)” selected from a list of the twenty standard
amino acid residues or a non-naturally occurring amino acid residue (id. at
col. 12, ll. 37-49).
As a variant with altered Fc gamma receptor binding affinity, Presta
refers to a polypeptide comprising an amino acid modification at “one or
more of” 66 amino acid positions of the Fc region, including position 280
(id. at col. 4, ll. 46-55). As a variant with improved Fc gamma receptor
binding, Presta refers to a polypeptide comprising an amino acid
modification at “one or more of” 32 amino acid positions of the Fc region,
including position 280 (id. at col. 5, ll. 31-40). As a variant with increased
FcγRII binding, Presta refers to a polypeptide comprising an amino acid
modification at “one or more of” 28 amino acid positions of the Fc region,
including position 280 (id. at col. 5, ll. 48-53). In addition, Presta identifies
16 amino acid positions, including position 280, as providing “improved
binding to FcγRII and no effect on FcγRIII binding” (id. at Table 2). At the
5
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: September 9, 2013